BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26894753)

  • 1. The Utility of Molecular Imaging in Prostate Cancer.
    Leiblich A; Stevens D; Sooriakumaran P
    Curr Urol Rep; 2016 Mar; 17(3):26. PubMed ID: 26894753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
    Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
    Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
    Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
    Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
    Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
    Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Fanti S
    PET Clin; 2015 Oct; 10(4):487-94. PubMed ID: 26384595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E; Gandaglia G; Robesti D; Rajwa P; Gomez Rivas J; Ibáñez L; Soeterik TFW; Bianchi L; Afferi L; Kesch C; Darr C; Guo H; Zhuang J; Zattoni F; Fendler WP; Amparore D; Huebner NA; Giesen A; Joniau S; Schiavina R; Brunocilla E; Mattei A; Dal Moro F; Moreno Sierra J; Porpiglia F; Picchio M; Chiti A; van den Bergh R; Shariat SF; Montorsi F; Briganti A
    Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
    Sterzing F; Kratochwil C; Fiedler H; Katayama S; Habl G; Kopka K; Afshar-Oromieh A; Debus J; Haberkorn U; Giesel FL
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):34-41. PubMed ID: 26404016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
    Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M
    J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Lavalaye J; Lam MG; Verzijlbergen JF; Krijger GC; Vis R; de Keizer B
    Ned Tijdschr Geneeskd; 2015; 160():A9780. PubMed ID: 27142500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Place of molecular imaging in the management of prostate cancer].
    Rousseau C; Le Thiec M; Maucherat B; Frindel M; Fleury V
    Cancer Radiother; 2021 Oct; 25(6-7):663-666. PubMed ID: 34404605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
    Valle L; Shabsovich D; de Meerleer G; Maurer T; Murphy DG; Nickols NG; Vapiwala N; Calais J; Kishan AU
    Eur Urol Oncol; 2021 Jun; 4(3):339-355. PubMed ID: 33637464
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
    Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
    Krause BJ; Souvatzoglou M; Treiber U
    Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.